Progressive Multifocal Leukoencephalopathy during Ixazomib-Based Chemotherapy
1
Division of Physical Medicine and Rehabilitation, Department of Medicine, The University of Toronto, Toronto, ON, Canada
2
Department of Clinical Neurological Sciences, Western University, London, ON, Canada
3
Division of Hematology, Department of Medicine, Western University, London, ON, Canada
4
Department of Ophthalmology, Western University, London, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(1), 99-102; https://doi.org/10.3747/co.25.3674
Submission received: 7 November 2017
/
Revised: 5 December 2017
/
Accepted: 4 January 2018
/
Published: 1 February 2018
Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system that most often affects immunocompromised individuals. It is caused by the reactivation of the John Cunningham virus (JCV), which is found in latent form in the majority of adults. We describe a 59-year-old man with multiple myeloma who developed severe neurological deficits during treatment with ixazomib-based chemotherapy. A diagnosis of PML was established with gadolinium-enhanced magnetic resonance imaging (MRI) and by detection of JCV in the cerebrospinal fluid. Despite cessation of chemotherapy and treatment with mirtazapine, he had an inexorable neurological decline and died two months after presenting to hospital. Multiple myeloma and its treatments can predispose patients to opportunistic infections including PML. Although there have been case reports of PML in patients with multiple myeloma treated with bortezomib (a different proteosome inhibitor), this is, to our knowledge, the first documented case of PML in a patient treated with a regimen that includes ixazomib.
Share and Cite
MDPI and ACS Style
Sawicki, C.P.; Climans, S.A.; Hsia, C.C.; Fraser, J.A. Progressive Multifocal Leukoencephalopathy during Ixazomib-Based Chemotherapy. Curr. Oncol. 2018, 25, 99-102. https://doi.org/10.3747/co.25.3674
AMA Style
Sawicki CP, Climans SA, Hsia CC, Fraser JA. Progressive Multifocal Leukoencephalopathy during Ixazomib-Based Chemotherapy. Current Oncology. 2018; 25(1):99-102. https://doi.org/10.3747/co.25.3674
Chicago/Turabian StyleSawicki, C.P., S.A. Climans, C.C. Hsia, and J.A. Fraser. 2018. "Progressive Multifocal Leukoencephalopathy during Ixazomib-Based Chemotherapy" Current Oncology 25, no. 1: 99-102. https://doi.org/10.3747/co.25.3674
